Latest advanced Therapies
Cross-border collaboration to support pricing and access for high-cost, high-value therapies: a review of initiatives in Europe

Yasmina Zegaoui and Eleanor Butler present recent research at ISPOR Europe reviewing cross-country collaboration models with a focus on health technology assessment

The introduction of a pan-European HTA: Shaping the landscape for future ATMP launches

An overview of the recent European policy updates and the implications they may have for the launch of ATMPs in Europe

BeNeLuxA initiative supports the reimbursement of Zolgensma® in Belgium, Ireland and the Netherlands

Yasmina Zegaoui, Consultant at Lightning Health, looks at how this managed entry agreement initiative can enable the reimbursement of a much-needed therapy for patients

ATMP market access: Advanced Therapies Congress & Expo 2021

Yasmina Zegaoui, Senior Consultant and Nasos Kipentzoglou, Senior Analyst at Lightning Health report on some of the key topics from the two-day event

Thinking Outside the Box: Sustainable Solutions to Drive Global Patient Access for Advanced Therapy Medicinal Products (ATMPs)

Lightning Health’s thought-leadership perspective on sustainable solutions to drive global patient access for ATMPs

ATMP Market Access: ensuring sustainable patient access to life-changing therapies

How Lightning Health can support you to navigate your access challenges associated with ATMPs

Retrospective analysis of NICE CAR-T therapy single technology appraisals and identification of strategies to minimise time to patient access

In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals

The G-BA implements post launch real world evidence generation for Zolgensma®

Nasos Kipentzoglou, Analyst and Eleanor Butler, Consultant at Lightning Health review the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma®

NICE rejects gene therapy Zynteglo

Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning Health explores why the beta thalassaemia treatment is not recommend for routine NHS funding